Minerva Neurosciences Inc. Registered Shares DL -,0001
- BID
3.772
- ASK
3.886
- 13,256 Units12,867 Units
- 07/23, 17:40:28 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
139.26%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-30.73 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 3.772 G | 0 Units |
| PRICE DETERMINATION TIME | 07/23/2026 / 05:31:48 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 3.824 | 3.672 |
| PREV. DAY'S PRICE | 3.876 | (07/22) |
| CHANGE DAY BEFORE | -0.10 | -2.68 % |
| 52 WEEK HIGH / LOW | 7.4 (03/16) | 1.46 (08/08) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -4.27 | 0.18 | -30.73 | -3.10 | -0.70 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | 11.69 | - | - | - |
PRICE - BOOK RATIO | - | - | - | - | - |
PRICE - SALES RATIO | - | - | - | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A3DMH5 |
| ISIN | US6033802058 |
| SYMBOL | 4MNA |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | MINERVA NEUROSC. DL-,0001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 2.76 % | -3.96 % | -37.58 % | 17.45 % | 139.26 % | -48.15 % | -71.06 % | 15.36 % |
| HIGH | 3.94 | 4.85 | 6.23 | 7.40 | 7.40 | 11.23 | 23.40 | 7.40 |
| LOW | 3.50 | 3.45 | 3.45 | 3.26 | 1.46 | 1.13 | 0.36 | 3.18 |
Dividende
pro Aktie
MINERVA NEUROSC. DL-,0001 does not deliver dividend information
Company profile
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.